<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01341132</url>
  </required_header>
  <id_info>
    <org_study_id>10-03278</org_study_id>
    <nct_id>NCT01341132</nct_id>
  </id_info>
  <brief_title>Evaluation of Cirrhosis and Malignant Hepatic Lesions Using Novel MR Contrast Agents</brief_title>
  <official_title>Evaluation of Cirrhosis and Malignant Hepatic Lesions Using Novel MR Contrast Agents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>San Francisco Veterans Affairs Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>San Francisco Veterans Affairs Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine whether or not gadoxetate disodium (Eovist) enhanced magnetic
      resonance imaging (MRI) has a higher sensitivity for detecting hepatocellular carcinoma
      (Liver Cancer) comparison to multi-detector computed tomography (CT).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>May 2011</start_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Suspected Liver Disease</arm_group_label>
    <description>Alpha-feto protein &gt; 400 ng / mL or
prior ultrasound with mass suspicious for hepatic malignancy or.
clinical risk of hepatocellular carcinoma or
prior multi-detector CT with mass suspicious for possible hepatocellular carcinoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI Scan of the Liver enhanced with Eovist</intervention_name>
    <description>10mL of gadoxetate disodium administered intravenously while being scanned via the MRI. Images will be attained on a 5, 10 and 20 minute delay. Expected scan time is 45 minutes total</description>
    <arm_group_label>Suspected Liver Disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        75 patients of the San Francisco VA Medical Center with suspected HCC identified on
        contrast-enhanced multi-detector CT, or on ultrasound and referred to contrast-enhanced
        multi-detector CT.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Alpha-feto protein &gt; 400 ng / mL or

          -  prior ultrasound with mass suspicious for hepatic malignancy or.

          -  clinical risk of hepatocellular carcinoma or

          -  prior multi-detector CT with mass suspicious for possible hepatocellular carcinoma

        Exclusion Criteria:

          -  Glomerulo-filtration rate &lt; 50 mL/ min/1.73 m2 based on a creatinine measurement
             within three months of the MR study

          -  Previous diagnosis of hepatic malignancy

          -  Any conditions that would discount the ability to have an MRI scan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rizwan Aslam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Francisco VA Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Francisco VA Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2011</study_first_submitted>
  <study_first_submitted_qc>April 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2011</study_first_posted>
  <last_update_submitted>April 21, 2011</last_update_submitted>
  <last_update_submitted_qc>April 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>Rizwan Aslam</name_title>
    <organization>San Francisco Veterans Administration Medical Center</organization>
  </responsible_party>
  <keyword>HCC</keyword>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>MRI</keyword>
  <keyword>Liver</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

